Analytical work gives every batch its evidence profile

A biologic product is not controlled by appearance, yield, or concentration alone. It must be identified, measured, challenged, released, trended, compared, and monitored through methods that match the product’s real risks.

For antibodies, that may mean aggregation, charge variants, glycosylation, potency, purity, and host-cell impurities. For enzymes, activity sits near the center. For viral vectors, physical titer and functional titer must be interpreted together. For plasmids, topology and endotoxin can decide whether the material is usable. For vaccines, potency and antigen quality carry the story.

CDMO Network offers analytical development and quality control CDMO services for monoclonal antibodies, bispecifics, Fc-fusions, recombinant proteins, enzymes, vaccines, viral vectors, plasmid DNA, nucleic-acid products, peptides, sterile injectables, lyophilized products, prefilled syringes, cartridges, and advanced modalities.

Manufacturing says, “We made it.” QC asks, “What exactly did you make?”

A batch can look successful in the bioreactor and still fail because the product aggregated, lost activity, shifted potency, changed charge profile, carried too much residual impurity, lost plasmid topology, or showed functional vector decline.

CDMO Network builds analytical and QC strategies around the product’s modality, development stage, release need, stability program, regulatory milestone, and future comparability risk.

A batch without strong analytics is just material with assumptions attached.

Analytical strategy begins with the product’s quality attributes

CDMO Network starts analytical work by defining what must be measured. Every product has a different quality fingerprint, and the right assay package depends on what could actually change the product’s safety, function, or quality.

• Antibodies: identity, purity, aggregation, potency, glycosylation, charge variants, residual Protein A, HCP, residual DNA, endotoxin, particles, and stability.
• Viral vectors: genome titer, particle titer, infectious titer, potency, residual plasmid, residual host-cell DNA, HCP, aggregation, and empty/full ratio where relevant.
• Plasmids: sequence identity, supercoiled percentage, topology, residual RNA, endotoxin, purity, and concentration.
• Enzymes: activity, specific activity, identity, purity, impurities, and stability.
• Vaccines: antigenicity, potency, adjuvant interaction, dose uniformity, particle structure, or infectivity.

The goal is not to run more tests. The goal is to run the tests that make the batch decision defensible.

Analytical method development creates the measurement system

Analytical method development creates procedures that can measure product quality with enough specificity and reliability for the stage. CDMO Network supports method development for identity, purity, potency, concentration, impurities, aggregation, charge variants, glycosylation, activity, infectivity, topology, antigenicity, residual impurities, particles, residual moisture, pH, osmolality, reconstitution, container closure, and stability.

The method must match the decision it supports. A development characterization method may help understand the product. A release method must support batch disposition. A stability method must detect change over time. A comparability method must detect meaningful differences after a process, site, scale, formulation, or container change.

A good method does not merely produce a number. It produces a number the program can use.

QC testing supports batch decisions

CDMO Network supports QC testing for drug substance, drug product, intermediates, reference standards, stability samples, comparability samples, engineering batches, toxicology material, clinical batches, commercial batches, and post-change batches.

• Identity, purity, potency, activity, and concentration
• Endotoxin, bioburden, sterility coordination, and mycoplasma
• Residual DNA, residual RNA, residual HCP, and residual Protein A
• Aggregation, charge variants, particles, pH, osmolality, and residual moisture
• Reconstitution, container closure integrity, visual inspection, and presentation-specific testing

QC is where the batch becomes a decision.

Potency and functional assays need special attention

Potency is often the most important and most difficult analytical category. CDMO Network supports potency assay development and functional testing for antibodies, enzymes, viral vectors, vaccines, recombinant proteins, plasmids, nucleic-acid products, and advanced modalities.

Potency may be measured through binding assays, cell-based assays, enzymatic activity, infectivity, transduction, antigenicity, neutralization, reporter systems, proliferation assays, inhibition assays, or product-specific functional readouts.

Impurity testing defines what does not belong

Biologic products carry process-related and product-related impurities. CDMO Network supports impurity testing strategies for host-cell protein, residual host-cell DNA, residual RNA, residual Protein A, residual plasmid, endotoxin, bioburden, process reagents, nuclease residues, chromatography leachables, aggregates, fragments, charge variants, clipped species, empty particles, degradation products, and presentation-related particles.

The product is partly defined by what has been removed.

Stability-indicating methods support shelf-life claims

Stability studies are only as strong as the methods used to measure change. CDMO Network supports development and execution of stability-indicating methods for biologics, proteins, enzymes, vaccines, vectors, plasmids, sterile injectables, lyophilized products, syringes, cartridges, and advanced products.

A product stored frozen may need post-thaw testing. A product stored refrigerated may need long-term potency and purity tracking. A lyophilized product may need residual moisture and reconstitution. A prefilled syringe may need particles and force performance.

A shelf-life claim is supported by methods that can see what time does to the product.

Product characterization gives deeper product understanding

Product characterization goes beyond routine release testing. CDMO Network supports characterization for proteins, antibodies, enzymes, viral vectors, plasmids, vaccines, peptides, and advanced modalities.

• Peptide mapping, intact mass, subunit mass, and glycan profiling
• Charge variant analysis and higher-order structure assessment
• Aggregation analysis, particle analysis, and activity profiling
• Antigenicity testing, infectivity testing, and potency-related characterization
• Plasmid topology analysis, sequence confirmation, impurity profiling, and orthogonal identity testing

Reference standards and control materials anchor the data

Reference standards keep analytical results interpretable over time. CDMO Network supports primary reference standards, working standards, assay controls, potency standards, activity standards, vector reference materials, plasmid controls, vaccine antigen references, qualification, bridging, storage, replacement, and lifecycle planning.

The standard is the ruler. If the ruler changes without control, the measurement system changes with it.

Method qualification, validation, and transfer

Analytical methods mature over the development lifecycle. CDMO Network supports phase-appropriate qualification, GMP validation, method transfer, bridging studies, robustness review, system suitability design, acceptance criteria, protocol preparation, report review, and receiving-lab readiness.

A method’s job changes as the program matures. The evidence supporting the method must mature with it.

Analytical and QC for antibodies and recombinant proteins

CDMO Network supports analytical and QC programs for antibodies, bispecifics, Fc-fusions, cytokines, growth factors, enzymes, and recombinant proteins.

For antibodies, relevant methods may include SEC, IEX, CE-SDS, cIEF, glycan analysis, peptide mapping, potency assays, binding assays, HCP, residual DNA, residual Protein A, endotoxin, particles, and stability testing. For bispecifics, additional methods may be needed for chain pairing, fragments, product-related impurities, and dual-binding function. For enzymes, activity and specific activity must be controlled alongside identity, purity, impurities, and stability.

A protein is not only present. It must be correct, pure, stable, and active.

Analytical and QC for viral vectors

Viral vector analytics need to connect physical and functional quality. CDMO Network supports analytical and QC testing for AAV, lentiviral vectors, adenoviral vectors, HSV-based vectors, oncolytic viruses, and other vector systems.

Relevant methods may include genome titer by qPCR or ddPCR, capsid or particle titer, infectivity, functional titer, potency, residual plasmid, residual host-cell DNA, host-cell protein, residual nuclease, aggregation, empty/full analysis where relevant, endotoxin, sterility coordination, mycoplasma, and stability testing.

Delivery is the point.

Analytical and QC for plasmids and nucleic acids

Plasmid and nucleic-acid analytics must protect identity, purity, and form. CDMO Network supports QC testing for plasmid DNA, linear DNA, mRNA-related templates, oligonucleotide-related products, guide RNA, and nucleic-acid products or inputs.

Relevant methods may include sequence confirmation, topology analysis, supercoiled percentage, residual RNA, residual host-cell DNA, host-cell protein, endotoxin, purity, concentration, identity, stability, and storage-condition testing.

The information must be right. The molecular form must remain usable.

Analytical and QC for vaccines

Vaccine analytics must preserve immune-relevant quality. CDMO Network supports QC testing for recombinant protein vaccines, viral vaccines, vector vaccines, VLPs, adjuvanted vaccines, antigen products, and advanced vaccine components.

Relevant methods may include antigen identity, antigenicity, potency, infectivity where relevant, protein purity, particle structure, adjuvant association, dose uniformity, residual impurities, endotoxin, sterility coordination, stability, and formulation compatibility.

The immune system responds to quality, not just quantity.

Analytical and QC for sterile drug product

Sterile drug product QC protects the final unit. CDMO Network supports QC testing for liquid vials, lyophilized vials, frozen products, prefilled syringes, cartridges, and infusion products.

Relevant tests may include appearance, identity, potency, activity, concentration, pH, osmolality, particles, visual inspection, endotoxin, sterility coordination, bioburden, container closure integrity, residual moisture, reconstitution time, syringe force, cartridge dose delivery, extractable volume, stability, and in-use testing.

The batch decision ends at the unit the patient receives.

Equipment and laboratory capability for analytical and QC services

Analytical and QC services require product-specific methods, qualified laboratories, GMP systems, and data review.

Relevant capabilities may include HPLC, UPLC, SEC, IEX, RP-HPLC, HIC, CE-SDS, cIEF, capillary electrophoresis, LC-MS, LC-MS/MS, peptide mapping, intact mass, subunit analysis, glycan analysis, UV-visible spectroscopy, fluorescence, DLS, MFI, light obscuration, NTA, ELISA, SPR, BLI, qPCR, ddPCR, cell-based potency assays, enzyme activity assays, infectivity assays, antigenicity assays, plasmid topology analysis, agarose gel methods, endotoxin, bioburden, sterility coordination, mycoplasma, residual DNA, residual RNA, HCP, residual Protein A, pH, osmolality, viscosity, residual moisture, reconstitution testing, CCIT, visual inspection, syringe force testing, and stability storage.

• Analytical method development and GMP QC testing
• Release testing and stability testing
• Potency, activity, infectivity, antigenicity, and topology assays
• Impurity, residual, and product characterization testing
• Reference standard and control material strategy
• Method qualification, validation, transfer, and lifecycle support

Quick summary

Analytical development and quality control CDMO services create the test system used to release, compare, monitor, and understand biologic products.

• Product-specific method development for identity, purity, potency, impurities, and stability
• GMP QC testing for drug substance, drug product, intermediates, and stability samples
• Potency, activity, infectivity, antigenicity, topology, and functional assay support
• Impurity testing for HCP, residual DNA, residual RNA, endotoxin, residual plasmid, and process residues
• Stability-indicating methods, characterization, and comparability testing
• Reference standard strategy, method qualification, validation, transfer, and lifecycle support

CDMO Network builds analytical and QC strategy around the product’s real decision points, not a generic test menu.

Requirements for high-quality analytical development and QC CDMO services

A high-quality analytical and QC program must measure the attributes that make the product acceptable. CDMO Network starts with product modality, critical quality attributes, manufacturing process, batch purpose, regulatory stage, release need, stability plan, comparability risk, drug product presentation, and method maturity.

We support analytical method development, GMP QC testing, release testing, stability testing, potency assay development, activity assays, infectivity assays, antigenicity assays, plasmid topology methods, impurity testing, residual testing, product characterization, stability-indicating methods, reference standard strategy, method qualification, method validation, method transfer, OOS support, and analytical lifecycle planning.

The right method changes the decision. The wrong method only adds a number.

A more exact model for analytical development & quality control CDMO services

Analytical development and QC services create the evidence system behind biologic manufacturing. They define how the product is identified, measured, released, trended, compared, stabilized, and investigated.

For biologics and advanced modalities, analytics must capture function as well as form: potency, activity, infectivity, topology, antigenicity, impurity profile, particles, stability, and final presentation performance.

Manufacturing creates the batch. Analytical and QC services decide whether the batch can be trusted.

Do you need a CDMO for analytical development or QC testing?

Contact CDMO Network to route analytical development, release testing, potency assay development, impurity testing, stability testing, method validation, or GMP QC support.